

Case Report

Trisomy 6 as the sole stemline abnormality in a patient with acute monocytic leukemia: a case report

Masahiro Manabe¹, Reiko Asada², Yuji Hagiwara², Dai Momose¹, Yasuyoshi Sugano¹, Takeshi Mazaki³, Ki-Ryang Koh¹

Departments of ¹Hematology, ²Clinical Laboratory, ³Pathology, Osaka General Hospital of West Japan Railway Company, 1-2-22 Matsuzaki-cho, Abeno-ku, Osaka 545-0053, Japan

Received February 23, 2018; Accepted March 20, 2018; Epub April 5, 2018; Published April 15, 2018

Abstract: It is rare for trisomy 6 to occur as the sole autosomal anomaly in hematological malignancies, but this finding has been reported to be associated with a hypoplastic bone marrow. We report the case of a 75-year-old male with acute monocytic leukemia, in which trisomy 6 was detected as the sole stemline abnormality. We also summarize the 26 published cases of acute myeloid leukemia involving isolated trisomy 6.

Keywords: Acute myeloid leukemia, trisomy 6, hyperplastic bone marrow

Introduction

The various biological and prognostic subgroups of myeloid malignancies are characterized by particular chromosomal abnormalities. Isolated trisomy 6 is a rare chromosomal abnormality in hematological malignancies. To the best of our knowledge, only 26 patients with acute myeloid leukemia (AML) and isolated trisomy 6 have been reported within the past three decades [1-17]. We wish to add a new case and to review the literature on this topic.

Case presentation

A 75-year-old male was admitted to our hospital because of dyspnea on effort, which had lasted for a month. A physical examination did not disclose any abnormal findings, apart from anemic conjunctivae and mild splenomegaly. A peripheral blood examination demonstrated a leukocyte count of $103.8 \times 10^9/L$ with a blastoid cell frequency of 89.0%, anemia (hemoglobin, 7.3 g/dL), and thrombocytopenia (platelet count, $80 \times 10^9/L$). Bone marrow aspiration revealed proliferating monoblasts and promonocytes, which accounted for 62.2% and 28.2% of all nucleated cells, respectively. These cells were positive for peroxidase and non-specific esterase (**Figure 1**). Flow-cytometric analysis showed that the cells that exhibited lower CD-

45 positivity, which was compatible with monoblasts, were positive for CD56, CD33, and human leukocyte antigen (HLA)-DR and negative for CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD13, CD14, CD16, CD19, CD20, CD34, and CD41. The other population, which demonstrated higher positivity for CD45 and were considered to be promonocytes, were positive for CD13, CD14, CD16, CD33, and HLA-DR and negative for CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD19, CD20, CD34, and CD41. Cytogenetic studies of the bone marrow cells detected isolated trisomy 6 as a stemline abnormality (**Figure 2**). Thus, a diagnosis of acute monocytic leukemia was made. We recommended that the patient should receive induction chemotherapy; however, he opted for outpatient treatment, mainly supportive care, because of economic issues. Although red cell and platelet transfusions as well as antibiotics were administered, he died of disease progression three months after the initial diagnosis of leukemia.

Discussion

Various types of trisomy are known to be associated with hematological malignancies [5]. Of these, trisomy 8 is one of the most well documented anomalies, especially with regard to its clinical impact on patient prognosis. However,

AML (M5) harboring trisomy 6




Figure 1. Bone marrow cells with hyperplasia. May-Giemsa-stained blasts are shown (A, $\times 400$; B, $\times 1000$). The blasts were positive for myeloperoxidase staining (C, $\times 1000$) and negative for non-specific esterase staining (D, $\times 1000$).




Figure 2. The G-banded karyogram obtained in this case 47,XY,+6.

the occurrence of trisomy 6 as a sole autosomal abnormality is rare in AML. To the best of our knowledge, only 26 cases of AML that harbored trisomy 6 as a sole autosomal abnormality have been reported in the last three decades [1-17]. **Table 1** shows the characteristics of the 27 reported cases (including the present case). The condition displayed a slight female pre-

dominance (M:F=11:16), and it was more common among adults, with 4, 9, and 11 cases seen in the ≤ 20 years, 20-40 years, and >40 years age groups, respectively.

Regarding the characteristics of cases of AML involving isolated trisomy 6, Gupta et al. pointed out that patients with this condition usually exhibited a hypocellular bone marrow and dyserythropoiesis, and they proceeded from aplastic anemia to AML in most of the published cases [16]. On the other hand, a hyperplastic bone marrow was observed in our case, and there have also been several other reports of such hyperplasia [7, 15]. Hence, cases of AML involving trisomy 6 do not always demonstrate a hypoplastic bone marrow. As for the phenotypes seen in AML patients with isolated trisomy 6, among the 21 described cases there were 8 cases of AML-M2, 5 cases of AML-M1, 4 cases of AML-M5 (including our case), 2 cases of AML-M4, and 1 case each of AML-M3 and AML-M7. Hence, there were no obvious characteristics, except that no cases of AML-M6 have been reported. Concerning surface marker analysis, although few reports have described the findings of such evaluations, it has been claimed that positivity for CD34 and HLA-DR is a characteristic of the primitive state of blasts [16]. However, in our case while the leukemic monoblasts and promonocytes

were negative for CD34 they were positive for HLA-DR. In addition, there was also a case in which the leukemic cells were negative for both of these molecules [7]. Hence, no particular surface antigen features were identified. In conclusion, Yu et al. reported that they could not identify any correlation between morphology or prognosis and the presence of trisomy 6

AML (M5) harboring trisomy 6

Table 1. Cases of acute myeloid leukemia involving isolated trisomy 6 reported in the last 3 decades

Case no.	Age/Sex	Diagnosis	WBC ($\times 10^9/L$)	Hb (g/dL)	Plt ($\times 10^9/L$)	G-banded Karyotype	Author
1	24/F	Acute monoblastic leukemia (FAB type M5)	NR	NR	NR	47,XX,+6	Weh HJ (1988)
2	1/F	Acute myeloblastic leukemia with mturation (FAB type M2)	79.6	NR	NR	47,XX,+6/48,idem,+8/49,idem,+3,+8	Petković I (1992)
3	NR/F	Acute myeloblastic leukemia with mturation (FAB type M2)*	NR	NR	NR	47,XX,+6	Berger R (1992)
4	81/M	Acute myeloblastic leukemia with mturation (FAB type M2)	NR	NR	NR	47,XY,+6	Chan LC (1992)
5	55/M	Acute myeloblastic leukemia with mturation (FAB type M2)	NR	NR	NR	47,XY,+6	UKCCG (1992)
6	8/M	Acute promyelocytic leukemia (FAB type M3)	NR	NR	NR	47,XY,+6	UKCCG (1992)
7	32/F	Acute monoblastic leukemia (FAB type M5)	NR	NR	NR	47,XX,+6	UKCCG (1992)
8	63/F	Acute myeloid leukemia, NOS*	4.8	13.5	6	47,XX,+6	Jonveaux P (1994)
9	28/F	Acute myeloblastic leukemia with mturation (FAB type M2)	4	11	53	47,XX,+6	Jonveaux P (1994)
10	37/F	Acute myeloblastic leukemia without mturation (FAB type M1)	5.1	12.2	11	47,XX,+6	Mohamed AN (1998)
11	66/F	Acute myelomonocytic leukemia (FAB type M4)	2.6	8.1	51	47,XX,+6	Mohamed AN (1998)
12	74/M	Acute myeloblastic leukemia without mturation (FAB type M1)	29.4	9.3	26	47,XY,+6	Mohamed AN (1998)
13	22/M	Acute myeloblastic leukemia without mturation (FAB type M1)	4.4	12.5	238	47,XY,+6	Mohamed AN (1998)
14	40/M	Acute myeloblastic leukemia without mturation (FAB type M1)	86.5	11.1	63	47,XY,+6	Mohamed AN (1998)
15	13/F	Acute myeloblastic leukemia with mturation (FAB type M2)	NR	NR	NR	47,XX,t(2;14)(q?24;q?24)c,+6	Huhta T (1999)
16	NR/M	Acute myeloid leukemia, NOS	NR	NR	NR	46,XY,+6,der(14;15)(q10;q10)c	Raimondi SC (1999)
17	41/F	Acute myeloid leukemia, NOS	NR	NR	NR	47,XX,+6	de Souza Fernandez T (2000)
18	NR/F	Acute myeloid leukemia, NOS	NR	NR	NR	47,XX,+6	Kerndrup GB (2001)
19	61/F	Acute myeloid leukemia, NOS	NR	NR	NR	47,XX,+6	Beyer V (2004)
20	22m/M	Acute megakaryoblastic leukemia (FAB type M7)	16.4	7.6	6	47,XY,+6	McCullough SJ (2004)
21	8/F	Acute myeloblastic leukemia with mturation (FAB type M2)	NR	NR	NR	47,XX,+6	Koh KN (2014)
22	51/M	Acute myeloblastic leukemia without mturation (FAB type M1)	20.77	13.5	4	47,XY,+6	Yu S (2014)
23	25/F	Acute myeloblastic leukemia with mturation (FAB type M2)	82.94	8	109	47,XX,+6	Yu S (2014)
24	82/M	Acute myelomonocytic leukemia (FAB type M4)	5.08	6.4	21	47,XY,+6	Yu S (2014)
25	21/F	Acute monoblastic leukemia (FAB type M5)	56.3	5.4	85	47,XX,+6	Gupta M (2015)
26	50/F	Acute myeloid leukemia, NOS†	NR	8.5	11	47,XX,+6	Aydın MS (2017)
27	75/M	Acute monocytic leukemia (FAB type M5)	103.8	7.3	80	47,XY,+6	Present case

FAB, French-American-British classification; NR, not reported; NOS, not otherwise specified. *in relapse. †therapy-related.

as a sole autosomal abnormality in AML [15], and we did not detect any obvious surface marker characteristics among such cases. Further accumulation of cases is necessary to obtain accurate data regarding the bone marrow cellularity, phenotype, and frequency of trisomy 6 within AML.

Disclosure of conflict of interest

None.

Address correspondence to: Masahiro Manabe, Department of Hematology, Osaka General Hospital of West Japan Railway Company, 1-2-22 Matsuzakicho, Abeno-ku, Osaka 545-0053, Japan. Tel: 81-6-6628-2221; Fax: 81-6-6628-4707; E-mail: m115-3564@med.osaka-cu.ac.jp

References

[1] Weh HJ, Kuse R, Hoffmann R, Seeger D, Suci S, Kabisch H, Ritter J, Hossfeld DK. Prognostic significance of chromosome analysis in de novo acute myeloid leukemia (AML). *Blut* 1988; 56: 19-26.

[2] Petković I, Konja J, Nakić M. Cytogenetic analysis in children with acute nonlymphocytic leukemia. *Cancer Genet Cytogenet* 1992; 58: 155-9.

[3] Berger R, Le Coniat M, Derré J, Flexor MA. Loss of chromosome 22 in patients with refractory anemia with excess of blasts (RAEB) in transformation and acute leukemia after RAEB. *Cancer Genet Cytogenet* 1992; 61: 210-2.

[4] Chan LC, Kwong YL, Liu HW, Chan TK, Todd D, Ching LM. Cytogenetic analysis of hematologic malignancies in Hong Kong. A study of 98 cases. *Cancer Genet Cytogenet* 1992; 62: 154-9.

[5] United Kingdom Cancer Cytogenetics Group (UKCCG). Primary, single, autosomal trisomies associated with haematological disorders. *Leuk Res* 1992; 16: 841-51.

[6] Jonveaux P, Fenaux P, Berger R. Trisomy 6 as the sole chromosome abnormality in myeloid disorders. *Cancer Genet Cytogenet* 1994; 74: 150-2.

[7] Mohamed AN, Varterasian ML, Dobin SM, McConnell TS, Wolman SR, Rankin C, Willman CL, Head DR, Slovak ML. Trisomy 6 as a primary karyotypic aberration in hematologic disorders. *Cancer Genet Cytogenet* 1998; 106: 152-5.

[8] Huhta T, Vettenranta K, Heinonen K, Kanerva J, Larramendy ML, Mahlamäki E, Saarinen-Pihkala UM, Knuutila S. Comparative genomic hybridization and conventional cytogenetic analyses in childhood acute myeloid leukemia. *Leuk Lymphoma* 1999; 35: 311-5.

[9] Raimondi SC, Chang MN, Ravindranath Y, Behm FG, Gresik MV, Steuber CP, Weinstein HJ, Carroll AJ. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. *Blood* 1999; 94: 3707-16.

[10] de Souza Fernandez T, Ornellas MH, Otero de Carvalho L, Tabak D, Abdelhay E. Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia. *Leuk Res* 2000; 24: 839-48.

[11] Kerndrup GB, Kjeldsen E. Acute leukemia cytogenetics: an evaluation of combining G-band karyotyping with multi-color spectral karyotyping. *Cancer Genet Cytogenet* 2001; 124: 7-11.

[12] Beyer V, Castagné C, Mühlematter D, Parlier V, Gmür J, Hess U, Kovacovics T, Meyer-Monard S, Tichelli A, Tobler A, Jacky E, Schanz U, Bargetzi M, Hagemeijer A, de Witte T, van Melle G, Jotterand M. Systematic screening at diagnosis of -5/del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics. *Cancer Genet Cytogenet* 2004; 152: 29-41.

[13] McCullough SJ, Neat MJ, Power M, O'marcaigh A. Trisomy 6 in a child with acute megakaryoblastic leukemia (AML-M7). *Cancer Genet Cytogenet* 2004; 154: 190-2.

[14] Koh KN, Lee JO, Seo EJ, Lee SW, Suh JK, Im HJ, Seo JJ. Clinical significance of previously cryptic copy number alterations and loss of heterozygosity in pediatric acute myeloid leukemia and myelodysplastic syndrome determined using combined array comparative genomic hybridization plus single-nucleotide polymorphism microarray analyses. *J Korean Med Sci* 2014; 29: 926-33.

[15] Yu S, Kwon MJ, Lee ST, Woo HY, Park H, Kim SH. Analysis of acute myeloid leukemia in Korean patients with sole trisomy 6. *Ann Lab Med* 2014; 34: 402-4.

[16] Gupta M, Radhakrishnan N, Mahapatra M, Saxena R. Trisomy chromosome 6 as a sole cytogenetic abnormality in acute myeloid leukemia. *Turk J Haematol* 2015; 32: 77-9.

[17] Aydın MS, Bozkurt S, Güneş G, Malkan ÜY, Aslan T, Eteğül S, Büyükaşık Y, Haznedaroğlu İC, Sayinalp N, Göker H, Demiroğlu H, Özcebe Oİ, Aksu S. Sole infrequent karyotypic aberration trisomy 6 in a patient with acute myeloid leukemia and breast cancer in remission. *Turk J Haematol* 2017; 34: 103-104.